by Landon Gray
The FDA expanded the indication for risankizumab-rzaa (Skyrizi, AbbVie) as the first specific interleukin-23 inhibitor for the treatment of moderate to severe Crohn’s disease in adults.
Risankizumab showed significant improvement in clinical and endoscopic responses in two induction trials and one maintenance trial, according to a company release.